The new facility will be used for manufacturing, R&D and administrative functions. It is especially suited to support FDA-compliant manufacturing of the company’s human stem cell products for various commercial applications in medical research, pharmaceutical manufacturing, drug discovery and cell therapy of diabetes and other diseases.
The company is leasing the facility from a third party at a rate comparable to its prior facility leases.
Jim Musick, president and CEO of Vitro, said: “We are very pleased to announce the opening of our new facility which affords us the appropriate infrastructure to provide stem cell products that are manufactured to stringent specifications when combined with new manufacturing equipment that the company has recently acquired.”